Specific immunotherapy for occupational latex allergy

Pereira, Celso; Rico, Pilar; Lourenço, Margarida; Lombardero, M.; Pinto‐Mendes, J; Chieira, C

doi:10.1034/j.1398-9995.1999.00954.x

Cited by 53 publications

(23 citation statements)

References 8 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 There have been reports of several individual cases of latex allergy successfully treated with latex extracts. 39,40 Two placebo-controlled studies used standardized latex extracts prepared by 2 European commercial suppliers. They reported success in evaluating results with latex challenges and symptom diary cards.…”

Section: New Antigensmentioning

confidence: 99%

Immunotherapy: 1999-2004

Norman

2004

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Section: New Antigensmentioning

confidence: 99%

Immunotherapy: 1999-2004

Norman

2004

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…Avoidance of exposure and symptomatic treatment for adverse reactions form the mainstay of management for latex allergy with no currently available licensed extract for specific immunotherapy. The extreme anaphylactic potential of currently available unmodified natural rubber latex extracts has limited trials of conventional latex specific immunotherapy due to the high incidence of adverse events (2)(3)(4)(5)(6)(7)(8).…”

Section: Hypoallergenic Variants Of the Major Latex Allergen Hev B 6mentioning

confidence: 99%

Hypoallergenic Variants of the Major Latex Allergen Hev b 6.01 Retaining Human T Lymphocyte Reactivity

Drew

Eusebius

Kenins

et al. 2004

The Journal of Immunology

View full text Add to dashboard Cite

Hev b 6.01 is a major allergen of natural rubber latex with sensitization of 70–86% of latex glove-allergic subjects. Recently, we mapped the immunodominant T cell sites of Hev b 6.01 to the highly IgE-reactive hevein (Hev b 6.02) domain. Hev b 6.01 contains 14 cysteine residues with multiple disulphide bridges stabilizing tertiary conformation. With the goal of a standardized specific immunotherapy we developed hypoallergenic Hev b 6.01 mutants by site-directed mutagenesis of selected cysteine residues (3, 12, 17, and 41) within the Hev b 6.02 domain. Peptides corresponding to the Hev b 6.02 domain of two of the mutants were also synthesized. These mutants and peptide variants showed markedly decreased or ablated latex-allergic patient serum IgE binding by immunoblotting and ELISA. Basophil activation testing confirmed markedly decreased activation with successive cysteine substitutions of the mutants and complete abrogation with the Hev b 6.02 (Cys 3, 12, 17, 41 Ala) peptide. Retention of T cell reactivity is crucial for effective specific immunotherapy and all mutants and peptide variants maintained their latex-specific T cell reactivity. The ablated allergenicity but retained T cell reactivity of the Hev b 6.02 (Cys 3, 12, 17, 41 Ala) peptide suggests this peptide is a suitable candidate for inclusion in a latex immunotherapy preparation.

show abstract

“…In 1999, Pereira et al [18] described the successful use of subcutaneous immunotherapy in a radiologist technician with latex allergy. Two years later, these authors [19] described the use of subcutaneous immunotherapy in four patients (three adult females and a 13-year-old boy) with latex allergy. All patients had anaphylaxis due to latex allergy and orallatex-fruit syndrome.…”

Section: Immunotherapy For Latex Allergymentioning

confidence: 98%

Immunotherapy: an option in the management of occupational asthma?

Sastre

Quirce

2006

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

At present, subcutaneous immunotherapy with latex extract can only be considered experimental and must be administered by experienced allergists in a hospital setting, similarly to venom immunotherapy. Nevertheless, systemic reactions responded well to treatment. Further clinical trials on efficacy, safety and long-term effectiveness in immunoglobulin E-mediated occupational rhinitis and asthma are clearly needed. Since allergen avoidance is not always possible, no other etiologic treatment but immunotherapy can be offered to patients with occupational rhinitis/asthma.

show abstract

Specific immunotherapy for occupational latex allergy

Cited by 53 publications

References 8 publications

Immunotherapy: 1999-2004

Immunotherapy: 1999-2004

Hypoallergenic Variants of the Major Latex Allergen Hev b 6.01 Retaining Human T Lymphocyte Reactivity

Immunotherapy: an option in the management of occupational asthma?

Contact Info

Product

Resources

About